Treat your diabetes patients with expert precision.
These go-to educational assets cover the broad spectrum of diabetes care, from the latest breaking news covering clinical research outcomes, to gold-standard clinical practice guidelines and treatment recommendations.
Topics covered include
If you're interested in diabetes, you may enjoy episode 5 of the new AACE Podcasts.
A 78 year old male presents to endocrine clinic for diabetes evaluation after recent hospital stay for a heart failure exacerbation. His past medical history is significant for ESRD on hemodialysis, HFrEF with an EF of 35%, CAD s/p multiple stents, COPD on home O2, hypertension, and hyperlipidemia.
His diabetes medication regimen is presently lantus 20 units qHS, lispro 7 units TID AC, and glipizide XL 10mg qday.
A 45 year old male with type 2 diabetes comes to see his endocrinologist. His Hba1c had been 6.7 last visit 6 months back. HIs A1c has now has gone up to 8.2 on recent labs. He is currently on metformin 1000mg bid. The patient had been following carb counting but has been non-compliant with his diet lately. He reports fasting glucose in 150-230 range most days. He checks before dinner occasionally and reports glucose usually over 200. He denies any hypoglycemia.
Michael is a 48-year-old gentleman with T2DM since age of 38. He has background of ischemic heart disease, mixed hyperlipidemia and hypertension. He had a delayed presentation of an inferior myocardial infarction 3 months ago. He is currently treated with Metformin XR 1g twice daily, Sitagliptin 100mg once daily, perindopril 5mg once daily, bisoprolol 2.5mg once daily Atorvastatin 80mg once daily. His most recent labs showed:
The 2021 AACE Advanced Diabetes Technology Guideline is a comprehensive, evidence based clinical practice guideline addressing the latest advancements in technology options for patients with diabetes. Key recommendations include key metrics for Continuous Glucose Monitoring (CGM), integration of technology with insulin pumps, and what health care professionals need to know in terms of safety.
These 2015 clinical practice guidelines (CPGs) for developing a diabetes mellitus (DM) comprehensive care plan are an update of the 2011 American Association of Clinical Endocrinologists (AACE) Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan.
This algorithm for the comprehensive management of persons with type 2 diabetes (T2D) was developed to provide clinicians with a practical guide that considers the whole patient, his or her spectrum of risks and complications, and evidence-based approaches to treatment.
The 2021 AACE Advanced Diabetes Technology Guideline is a comprehensive, evidence based clinical practice guideline addressing the latest advancements in technology options for patients with diabetes. Key recommendations include key metrics for Continuous Glucose Monitoring (CGM), integration of technology with insulin pumps, and what health care professionals need to know in terms of safety.
This algorithm for the comprehensive management of persons with type 2 diabetes (T2D) was developed to provide clinicians with a practical guide that considers the whole patient, his or her spectrum of risks and complications, and evidence-based approaches to treatment.
This slide deck reviews emerging diabetes technology including continuous glucose monitoring (CGM), insulin pump and CGM integration and artificial pancreas/hybrid closed loop technology.
This slide deck is an overview of issues with insulin that should be considered with hospitalized patients.
What are the benefits of early insulinization? What strategies can you use to select and initiate insulin treatment in patients with Type 2 diabetes? This slide library discusses the answers to these questions and more.
For more in-depth information on all of our disease state resources, listen to AACE Podcast now. Our podcasts cover a wide range of endocrine science as well as discussion regarding our clinical guidelines.
In this 50-minute video presentation Dr. Pop-Busiu discusses diabetic neuropathies, evidence-based prevention and management strategies, current epidemiology trends and more.
Type 1 diabetes (T1D) is a chronic autoimmune disorder that occurs in genetically susceptible individuals and that may be precipitated by environmental factors.
Access the #AACE2021: Top 20 most popular sessions on-demand.
The new AACE Learning: Disease State Bundles are a comprehensive, one-stop-shop for clinical endocrinology knowledge and continued education with CME/MOC credits.
This bundle provides a collection of courses and media related to diabetes care.
Endocrine Practice, our official journal, keeps you on the leading edge of endocrine patient care.
Access a wide range of case reports, visual vignettes and commentary from noted endocrinology experts.
October 14, 2020
This World Diabetes Day, we at the American Association of Clinical Endocrinology (AACE) extend our support to those in the endocrine care team who help diabetes patients every day. Now with a new b
October 16, 2020
Lilly has launched “Insulin Affordability: Learn. Act. Share.” to encourage those who use Lilly insulin to:
Learn about our affordability options
September 15, 2020
Anyone with commercial insurance, and those without insurance at all, can continue filling their monthly prescription of Lilly insulins for $35 through this program.
A position statement by the American Association of Clinical Endocrinologists
Since its inception, the American Association of Clinical Endocrinologists (AACE) has advocated for the finest in endocrine education and state-of-the-art health-care delivery without regard to race, ethnicity, gender, age, country of origin, economic status, lifestyle, sexual orientation or domestic living arrangements.
Evidence-based medicine has generated many philosophical and pragmatic challenges to clinical care. Chief among these challenges is how to deliver culturally appropriate individualized endocrine care while adhering to evidence-based guidelines and algorithms developed for large heterogeneous populations.
AACE would like to thank the following companies for grants in support of the Diabetes Resource Center:
